Table 4. Frequency of cardiac adverse events (treated set).
| n (%) | Tiotropium Respimat 5 μg (n = 114) a | Tiotropium Respimat 2.5 μg (n = 114) a | Placebo Respimat (n = 57) a |
|---|---|---|---|
| Any cardiac adverse event | 5 (4.4) | 1 (0.9) | 0 |
| Palpitations b | 2 (1.8) | 1 (0.9) | 0 |
| Ventricular extrasystoles b | 2 (1.8) | 0 | 0 |
| Atrioventricular block, first degree b | 1 (0.9) | 0 | 0 |
| Extrasystoles b | 1 (0.9) | 0 | 0 |
| Prinzmetal’s angina | 1 (0.9) | 0 | 0 |
| Supraventricular extrasystoles b | 1 (0.9) | 0 | 0 |
| Tachycardia | 1 (0.9) | 0 | 0 |
aPatients were randomised 2:2:1 to the tiotropium Respimat 5 μg, tiotropium Respimat 2.5 μg and placebo Respimat groups, respectively.
bOne event from each category occurred in a single patient prior to Day 59.